334 related articles for article (PubMed ID: 25315765)
1. Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.
Nadauld LD; Garcia S; Natsoulis G; Bell JM; Miotke L; Hopmans ES; Xu H; Pai RK; Palm C; Regan JF; Chen H; Flaherty P; Ootani A; Zhang NR; Ford JM; Kuo CJ; Ji HP
Genome Biol; 2014 Aug; 15(8):428. PubMed ID: 25315765
[TBL] [Abstract][Full Text] [Related]
2. One patient, two lesions, two oncogenic drivers of gastric cancer.
Alsinet C; Ranzani M; Adams DJ
Genome Biol; 2014 Aug; 15(8):444. PubMed ID: 25222187
[TBL] [Abstract][Full Text] [Related]
3. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
[TBL] [Abstract][Full Text] [Related]
4. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.
Fang WB; Jokar I; Chytil A; Moses HL; Abel T; Cheng N
Clin Exp Metastasis; 2011 Apr; 28(4):351-66. PubMed ID: 21374085
[TBL] [Abstract][Full Text] [Related]
5. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer.
Qu Y; Zhang H; Duan J; Liu R; Deng T; Bai M; Huang D; Li H; Ning T; Zhang L; Wang X; Ge S; Zhou L; Zhong B; Ying G; Ba Y
Oncotarget; 2016 May; 7(22):33286-96. PubMed ID: 27120811
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.
Morris SM; Baek JY; Koszarek A; Kanngurn S; Knoblaugh SE; Grady WM
Hepatology; 2012 Jan; 55(1):121-31. PubMed ID: 21898503
[TBL] [Abstract][Full Text] [Related]
7. [Correlations of polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility to gastric cancer].
Zhou Y; Jin GF; Jiang GJ; Wang HM; Tan YF; Ding WL; Wang LN; Chen WS; Ke Q; Shen J; Xu YC; Shen HB
Ai Zheng; 2007 Jun; 26(6):581-5. PubMed ID: 17562261
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.
Wang B; Tang Q; Xu L; Teng X; Ding W; Ren G; Wang X
Mod Pathol; 2021 Jan; 34(1):42-50. PubMed ID: 32732929
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.
Zhong Y; Macgregor-Das A; Saunders T; Whittle MC; Makohon-Moore A; Kohutek ZA; Poling J; Herbst BT; Javier BM; Cope L; Leach SD; Hingorani SR; Iacobuzio-Donahue CA
Clin Cancer Res; 2017 Mar; 23(6):1607-1620. PubMed ID: 27637888
[No Abstract] [Full Text] [Related]
10. Wnt Signaling Shapes the Histologic Variation in Diffuse Gastric Cancer.
Togasaki K; Sugimoto S; Ohta Y; Nanki K; Matano M; Takahashi S; Fujii M; Kanai T; Sato T
Gastroenterology; 2021 Feb; 160(3):823-830. PubMed ID: 33217450
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.
Li LQ; Pan D; Chen Q; Zhang SW; Xie DY; Zheng XL; Chen H
Cell Physiol Biochem; 2018; 47(4):1533-1545. PubMed ID: 29940566
[TBL] [Abstract][Full Text] [Related]
12. Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Kuang G; Yang Z; Shan B
Mol Biol Rep; 2012 Oct; 39(10):9453-62. PubMed ID: 22722999
[TBL] [Abstract][Full Text] [Related]
13. Association of polymorphisms in transforming growth factor-β receptors with susceptibility to gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Chen Z; Yang Z; Kuang G
Mol Biol Rep; 2012 Apr; 39(4):4301-9. PubMed ID: 21785915
[TBL] [Abstract][Full Text] [Related]
14. Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms.
Morris SM; Davison J; Carter KT; O'Leary RM; Trobridge P; Knoblaugh SE; Myeroff LL; Markowitz SD; Brett BT; Scheetz TE; Dupuy AJ; Starr TK; Grady WM
Int J Cancer; 2017 Feb; 140(4):853-863. PubMed ID: 27790711
[TBL] [Abstract][Full Text] [Related]
15. THE STUDY OF THE EXPRESSION OF CDH1, KI67, P53 AND HER2 IN DIFFUSE GASTRIC CARCINOMA.
Muzashvili T; Tutisani A; Chabradze G; Beridze N; Museridze N
Georgian Med News; 2020 Feb; (299):147-150. PubMed ID: 32242863
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype analysis of F-helix mutations at the kinase domain of TGFBR2, including a type 2 Marfan syndrome familial study.
Zhang L; Gao LG; Zhang M; Zhou XL
Mol Vis; 2012; 18():55-63. PubMed ID: 22259224
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
Busch S; Acar A; Magnusson Y; Gregersson P; Rydén L; Landberg G
Oncogene; 2015 Jan; 34(1):27-38. PubMed ID: 24336330
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
19. Clinical prognostic factors for ovarian metastasis in women with gastric cancer.
Yook JH; Oh ST; Kim BS
Hepatogastroenterology; 2007; 54(75):955-9. PubMed ID: 17591102
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
